Control of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
SUMMARY 2-Oxoglutarate-dependent dioxygenases, including the EglN prolyl hydroxylases that regulate HIF, can be inhibited with drug-like molecules. EglN2 is estrogen-inducible in breast carcinoma cells and the lone Drosophila EglN interacts genetically with Cyclin D1. Although EglN2 is a non-essential gene we found that EglN2 inactivation decreases Cyclin D1 levels and suppresses mammary gland proliferation in vivo. Regulation of Cyclin D1 is a specific attribute of EglN2 among the EglN proteins and is HIF-independent. Loss of EglN2 catalytic activity inhibits estrogen-dependent breast cancer tumorigenesis and can be rescued by exogenous Cyclin D1. EglN2 depletion also impairs the fitness of lung, brain, and hematopoietic cancer lines. These findings support the exploration of EglN2 inhibitors as therapeutics for estrogen-dependent breast cancer and other malignancies. SIGNIFICANCE Cyclin D1 plays an important role in many cancers, including breast cancer. The observations described herein predict that inhibiting EglN2 catalytic activity will diminish Cyclin D1 levels in cancer cells and impair their ability to proliferate in vivo. Notably, EglN2 is estrogen-inducible and loss of either EglN2 or Cyclin D1 leads to mammary gland hypoproliferation. Therefore the relationship between EglN2 and Cyclin D1 might be especially relevant in hormone-sensitive breast cancer, where new therapies are needed for women who become refractory to estrogen antagonists. EglN2 appears to be an attractive drug target because EglN2 is not essential in mammals and it has already been established that enzymes of this class can be inhibited with drug-like small organic molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 2×
“In addition, EglN2 loss decreased Cyclin D1 in UOK101 and 769-P VHL / renal carcinoma cells, which constitutively produce HIF2a protein due to the absence of pVHL and produce neither HIF1a mRNA nor protein (Maxwell et al., 1999) (Figure 1D, Figure S2B, and data not shown).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
Self-citationGenes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922 · cited 2×
“mammary gland four as previously described (Minn et al., 2005).”
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“For example, HIF can transcriptionally activate REDD1, which inhibits mTOR activity (Brugarolas et al., 2004; Reiling and Hafen, 2004) and thereby decreases Cyclin D1 translation.”
Self-citationBerra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D., & Pouysségur, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg392 · Cited by 1,348
JmjC-domain-containing proteins and histone demethylation
Klose, R. J., Kallin, E. M., & Zhang, Y. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1945 · Cited by 1,290 · cited 2×
“The 2-oxoglutarate and iron-dependent dioxygenase superfamily includes the collagen prolyl and lysyl hydroxylases, the FTO and AlkB DNA demethylases, the JmjC-containing histone demethylases, the FIH1 asparaginyl hydroxylase, and the EglN family prolyl hydroxylases (Aravind and Koonin, 2001; Klose et al., 2006; Pollar…”
Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., & Semenza, G. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.3995-4004.2001 · Cited by 1,256 · cited 2×
“Although Her2 activation has been reported to activate HIF (Laughner et al., 2001; Li et al., 2005) we observed the clearest evidence of HIF activation, as determined by accumulation of canonical HIF-responsive mRNAs, in the ER-negative, Her2-negative breast cancers (A.”
Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406026200 · Cited by 1,108 · cited 7×
“For example, EglN3 is itself a HIF target, is induced by hypoxia, and has a lower oxygen Km than EglN1 (Appelhoff et al., 2004; Minamishima et al., 2009).”
InfluentialCyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 3×
“…an important role in many forms of cancer, including breast cancer, and is induced by estrogen in estrogenreceptor positive breast cancers (Bartkova et al., 1994; Landis et al., 2006; Roy and Thompson, 2006; Yu et al., 2001), we asked whether EglN2 activity affects Cyclin D1 activity.”
CDK-Independent Activation of Estrogen Receptor by Cyclin D1
Zwijsen, R. M. L., Wientjens, E., Klompmaker, R., van der Sman, J., Bernards, R., & Michalides, R. J. A. M. (1997) · Cell · doi:10.1016/s0092-8674(00)81879-6 · Cited by 720 · cited 1×
“Cyclin D1 also has kinase-independent functions related to ER signaling and mammary epithelial proliferation (Landis et al., 2006; Neuman et al., 1997; Yu et al., 2006; Zwijsen et al., 1997).”
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647 · cited 2×
“5 embryos as described previously (Kozar et al., 2004).”
Intracellular localisation of human HIF-1α hydroxylases:implications for oxygen sensing
Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Bürgel, T., Jelkmann, W., et al. (2003) · Journal of Cell Science · doi:10.1242/jcs.00318 · Cited by 432
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429 · cited 2×
“Cyclin D1 also has kinase-independent functions related to ER signaling and mammary epithelial proliferation (Landis et al., 2006; Neuman et al., 1997; Yu et al., 2006; Zwijsen et al., 1997).”
Takeda, K., Ho, V. C., Takeda, H., Duan, L.-J., Nagy, A., & Fong, G.-H. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00425-06 · Cited by 401
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329 · cited 4×
“…an important role in many forms of cancer, including breast cancer, and is induced by estrogen in estrogenreceptor positive breast cancers (Bartkova et al., 1994; Landis et al., 2006; Roy and Thompson, 2006; Yu et al., 2001), we asked whether EglN2 activity affects Cyclin D1 activity.”
InfluentialSafran, M., Kim, W. Y., O'Connell, F., Flippin, L., Günzler, V., Horner, J. W., DePinho, R. A., & Kaelin, W. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509459103 · Cited by 305 · cited 3×
“These enzymes C can be inhibited with drug-like small molecules that compete with 2-oxoglutarate or interfere with iron utilization, both in vitro and in vivo (Bruegge et al., 2007; Mole et al., 2003; Ozer and Bruick, 2007; Safran et al., 2006).”
Self-citationSomatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure
Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., & Kaelin, W. G. (2008) · Blood · doi:10.1182/blood-2007-10-117812 · Cited by 294 · cited 1×
“EglN1 (also called PHD2) is the primary prolyl hydroxylase responsible for HIF regulation (Berra et al., 2003; Minamishima et al., 2008; Takeda et al., 2008).”
Self-citationRegulation of adult erythropoiesis by prolyl hydroxylase domain proteins
Takeda, K., Aguila, H. L., Parikh, N. S., Li, X., Lamothe, K., Duan, L.-J., Takeda, H., Lee, F. S., & Fong, G.-H. (2008) · Blood · doi:10.1182/blood-2007-09-114561 · Cited by 263 · cited 1×
“EglN1 (also called PHD2) is the primary prolyl hydroxylase responsible for HIF regulation (Berra et al., 2003; Minamishima et al., 2008; Takeda et al., 2008).”
Non-heme dioxygenases: cellular sensors and regulators jelly rolled into one?
Ozer, A., & Bruick, R. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio863 · Cited by 214 · cited 2×
“These enzymes C can be inhibited with drug-like small molecules that compete with 2-oxoglutarate or interfere with iron utilization, both in vitro and in vivo (Bruegge et al., 2007; Mole et al., 2003; Ozer and Bruick, 2007; Safran et al., 2006).”
Hsieh, M. M., Linde, N. S., Wynter, A., Metzger, M., Wong, C., Langsetmo, I., Lin, A., Smith, R., Rodgers, G. P., Donahue, R. E., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073254 · Cited by 171
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo
Minamishima, Y. A., Moslehi, J., Padera, R. F., Bronson, R. T., Liao, R., & Kaelin, W. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00331-09 · Cited by 161 · cited 15×
“Our findings, together with previously published work, indicate that EglN1 has been retained as the primary HIF regulator under normal conditions and that EglN2 and EglN3, in addition to regulating HIF, have assumed HIF-independent roles in the control of proliferation and apoptosis, respectively.”
InfluentialSelf-citation2-Oxoglutarate analogue inhibitors of hif prolyl hydroxylase
Mole, D. R., Schlemminger, I., McNeill, L. A., Hewitson, K. S., Pugh, C. W., Ratcliffe, P. J., & Schofield, C. J. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00539-0 · Cited by 145 · cited 2×
“These enzymes C can be inhibited with drug-like small molecules that compete with 2-oxoglutarate or interfere with iron utilization, both in vitro and in vivo (Bruegge et al., 2007; Mole et al., 2003; Ozer and Bruick, 2007; Safran et al., 2006).”
Cited by
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
D’Hulst, G., Soro-Arnaiz, I., Masschelein, E., Veys, K., Fitzgerald, G., Smeuninx, B., Kim, S., Deldicque, L., Blaauw, B., Carmeliet, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13889-6 · Cited by 2,310
Martinez-Outschoorn, U. E., Lisanti, M. P., & Sotgia, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.005 · Cited by 423
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Self-citationRegulation of cell proliferation by hypoxia-inducible factors
Hubbi, M. E., & Semenza, G. L. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00279.2015 · Cited by 300
Metadata
- Authors
- Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H.-W., Boehm, J. S., Ni, M., Geisen, C., Root, D. E., Polyak, K., Brown, M., Richardson, A. L., Hahn, W. C., Kaelin, W. G., & Bommi-Reddy, A.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 16
- Issue
- 5
- Pages
- 413-424
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2089033254
- Cited by
- 139
- References
- 26
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.